clinical management of synthetic cannabinoid toxicity

DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I

By Benjamin Caplan, MD

Comments Off on DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I

June 9, 2026

3 Min Read

The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…